Pharmaceutical settlement shows how great injury costs can be
A recent agreement made by GlaxoSmithKline illustrates the depth of damages that can arise from personal injury lawsuits over defective products and failure to warn consumers. According to the New York Times, this agreement stipulates that the company will pay $3 billion to settle allegations of illegal drug marketing and fraud against Medicaid.
This is the largest pharmaceutical settlement to date, breaking previous records of $2.3 billion and $1.4 million settlements. The product that was the focus of this lawsuit is the drug Avandia and the company’s methods of marketing it to doctors. Also under legal scrutiny by the U.S. Justice Department were the company’s alleged manipulation of research. Continue reading
Nordica USA pays $214,000 penalty, continues to deny withholding defect
Dangerous products should not be placed on consumer shelves at all. They should not ever enter into the stream of commerce where they could cause injury to a purchaser. We all know that mistakes do happen, and that sometimes a dangerous product does make its way into the mainstream population.
When this happens and the manufacturer becomes aware of the defective product, it is their duty to make the consumer aware that the product could cause them harm. Longtime ski-maker Nordica USA agreed to settle allegations that the company was aware of a defect in one model of skis that could cause serious injury to the user. Continue reading